Tilray Brands Inc
TSX:TLRY
Tilray Brands Inc
Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs.
Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.
Record Revenue: Tilray reported record annual revenue of $821 million for fiscal 2025, up 4% year-over-year, though this missed the lower end of revised guidance due to weaker beverage sales and export delays.
Strong Cannabis Margins: Total cannabis gross margin rose 400 basis points to 44% in Q4, and grew 700 basis points for the year, supported by a focus on higher-margin products and international sales.
International Growth: International cannabis revenue hit a quarterly record of $22.4 million in Q4, up 71% year-over-year, with Germany and other European markets driving growth.
Beverage Headwinds: Beverage revenue rose 19% for the year, but Q4 was weak due to lower consumer demand and SKU rationalization. Cost savings initiatives are underway to improve future performance.
Large Impairment: The company took a $2 billion noncash impairment charge for the fiscal year due to declines in market cap and regulatory delays, resulting in a net loss of $2.2 billion.
Adjusted EBITDA Guidance: For fiscal 2026, Tilray guided to adjusted EBITDA of $62–72 million, expecting improvements from growth, operational efficiencies, and cost savings.
Balance Sheet Strength: Tilray ended the year with $256 million in cash, reduced net debt to $19 million, and improved its net debt-to-EBITDA ratio to 0.3x.
You don't have any saved screeners yet
